Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer

de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Kantoff, 1999, Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study, J Clin Oncol, 17, 2506, 10.1200/JCO.1999.17.8.2506 Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 Beer, 2007, Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC), J Clin Oncol, 25 Higano, 2009, Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer, Cancer, 115, 3670, 10.1002/cncr.24429 Small, 2006, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer, J Clin Oncol, 24, 3089, 10.1200/JCO.2005.04.5252 Small, 2000, Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells, J Clin Oncol, 18, 3894, 10.1200/JCO.2000.18.23.3894 Fleming, 2008, Identifying and addressing safety signals in clinical trials, N Engl J Med, 359, 1400, 10.1056/NEJMe0807372 2005 Dillman, 1999, Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy, Cancer Metastasis Rev, 18, 465, 10.1023/A:1006341717398 Kirkwood, 2000, High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190, J Clin Oncol, 18, 2444, 10.1200/JCO.2000.18.12.2444 Maggi, 2011, Acute infusion reactions induced by monoclonal antibody therapy, Expert Rev Clin Immunol, 7, 55, 10.1586/eci.10.90 Sheikh, 2008, CD54 is a surrogate marker of antigen presenting cell activation, Cancer Immunol Immunother, 57, 1381, 10.1007/s00262-008-0474-9 Alberts, 2005 Ibrahim, 2005 Cunha, 2006, Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues, Cancer Lett, 236, 229, 10.1016/j.canlet.2005.05.021